5,777 results on '"*AFATINIB"'
Search Results
2. LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
3. Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
4. Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
5. Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
6. A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. (DELINOR)
7. A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma (Afatinib)
8. Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
9. Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer
10. Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma
11. Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
12. Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC
13. BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study) (BEAR)
14. EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study (ERIS)
15. Afatinib With CT and RT for EGFR-Mutant NSCLC
16. Pilot Trial for Treatment of Recurrent Glioblastoma
17. Afatinib in Advanced Refractory Urothelial Cancer
18. Observational Study of Afatinib 30 mg Daily
19. Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations
20. Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.
21. Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)
22. Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
23. Afatinib in Advanced NRG1-Rearranged Malignancies
24. An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
25. Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer
26. Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
27. S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
28. Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer (NSCLC)
29. Real-World Data Presenting the Descriptive Analysis of the Use of Tyrosine Kinase Inhibitors (TKIs) Among Metastatic Non–Small-Cell Lung Cancer (mNSCLC) Patients in Qatar: A Nationwide Retrospective Cohort Study.
30. Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs.
31. A novel role for WZ3146 in the inhibition of cell proliferation via ERK and AKT pathway in the rare EGFR G719X mutant cells.
32. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects.
33. In Silico Molecular Modeling of Four New Afatinib Derived Molecules Targeting the Inhibition of the Mutated Form of BCR-ABL T315I.
34. Protein Kinase Inhibitors Indicated for Lung Cancer: Pharmacodynamics, Pharmacokinetics, Adverse Drug Reactions, and Evaluation in Clinical Trials.
35. The Change of Original‐ and Generic‐Targeted Antitumor Drugs under the National Centralized Drug Procurement Policy in Hohhot: An Interrupted Time‐Series Analysis.
36. Identification of potential inhibitors for drug-resistant EGFR mutations in non-small cell lung cancer using whole exome sequencing data.
37. Afatinib‐induced toxic epidermal necrolysis: A case report with a literature review.
38. Nuclear Receptors and Stress Response Pathways Associated with the Development of Oral Mucositis Induced by Antineoplastic Agents.
39. Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
40. Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma
41. Cambridge Brain Mets Trial 1 (CamBMT1)
42. The START Study Observes Afatinib as First-line Treatment and Sequential Therapy in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Nonsmall Cell Lung Cancer
43. The Drug Rediscovery Protocol (DRUP Trial) (DRUP)
44. Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma (neoCHANCE-1)
45. Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC (neoCHANCE-2)
46. Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
47. Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity (DARWIN1)
48. Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
49. Biomarker-based Study in R/M SCCHN (UPSTREAM)
50. Inhaled delivery of cetuximab-conjugated immunoliposomes loaded with afatinib: A promising strategy for enhanced non-small cell lung cancer treatment.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.